Compare GT & VERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GT | VERA |
|---|---|---|
| Founded | 1898 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Automotive Aftermarket | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.1B |
| IPO Year | 2005 | 2021 |
| Metric | GT | VERA |
|---|---|---|
| Price | $4.43 | $28.60 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 10 | 15 |
| Target Price | $7.31 | ★ $74.20 |
| AVG Volume (30 Days) | ★ 8.8M | 1.9M |
| Earning Date | 11-02-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $18,280,000,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.43 | $863.11 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.35 | $23.05 |
| 52 Week High | $10.62 | $56.05 |
| Indicator | GT | VERA |
|---|---|---|
| Relative Strength Index (RSI) | 29.64 | 38.59 |
| Support Level | N/A | N/A |
| Resistance Level | $6.33 | $36.95 |
| Average True Range (ATR) | 0.15 | 1.42 |
| MACD | -0.01 | -0.37 |
| Stochastic Oscillator | 9.62 | 29.24 |
Goodyear Tire & Rubber Co manufactures and sells a variety of rubber tires under the Goodyear brand name. The firm's tires are used for automobiles, trucks, buses, aircraft, motorcycles, mining equipment, farm equipment, and industrial equipment. The company operates its business through three operating segments representing its regional tire businesses: Americas; Europe, the Middle East, and Africa (EMEA); and the Asia Pacific. The majority of its revenue is generated from the Americas business, which develops, manufactures, distributes, and sells tires and related products and services in North, Central, and South America, along with selling tires to various export markets, mainly through intersegment sales.
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.